Skip to main content
. 2017 Aug 28;1(20):1645–1649. doi: 10.1182/bloodadvances.2017009613

Figure 2.

Figure 2.

Baseline vs end-of-infusion p65-phospho NF-κB iNKT cell activation. Points below the black line represent patients who achieved the primary outcome measure of a p65-phospho-NF-κB iNKT cell activation at 48 hours that was a >30% reduction from baseline. Subjects in the regadenoson and placebo arms are represented by red and white circles, respectively.